EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Janus Kinase Inhibitors for Acute Severe Ulcerative Colitis: Comparing Upadacitinib to Tofacitinib and Rescue to Sequential Salvage Therapy

Robert Gilmore, Richard Fernandes, Naeman Goetz, Simone Chin, Daniel Con, Peter De Cruz, Kathryn Demase, Miles P Sparrow, Sarah Lucas, Mayur Garg, Zachary Tuttle, Nicholas Clark und 23 weitere

Clinical Gastroenterology and Hepatology · 2026-09

DOI: 10.1016/j.cgh.2026.09.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-09. Verfasst von Robert Gilmore und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Mater Hospital, Brisbane, Australia; Mater Research Institute, University of Queensland, South Brisbane, Australia. E…. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Acute severe ulcerative colitis (ASUC) remains a medical emergency with limited therapeutic options. Upadacitinib and tofacitinib are Janus kinase (JAK) inhibitors being increasingly used as rescue therapy for ASUC with limited data. We evaluated the outcomes of JAK inhibitor use for ASUC over 52 weeks. METHODS: We undertook a multicenter retrospective cohort study across 13 Australian inflammatory bowel disease centers. Adults with ASUC who commenced upadacitinib or tofacitinib from April 2021 to April 2024 were included. Outcomes were assessed during index admission, and at weeks 8, 16, and 52. Comparisons of upadacitinib vs tofacitinib and rescue vs sequential salvage therapy were undertaken. The primary outcome for both analyses was colectomy by week 52. RESULTS: A total of 150 patients were included with complete follow-up to 52 weeks. Upadacitinib was used in 51%, tofacitinib in 49%; JAK inhibitors as rescue therapy in 69% and sequential salvage therapy in 31%. Colectomy occurred in 33% of patients by week 52 and was significantly lower with upadacitinib than tofacitinib (23.4% vs 42.5%; weighted marginal risk difference, -0.18; P = .022), with no significance at earlier timepoints. Sequential salvage therapy resulted in a numerically higher rate of colectomy compared with rescue therapy (38% vs 30%; adjusted marginal risk difference, -0.1; P = .239) but did not meet statistical significance. CONCLUSIONS: JAK inhibitors were effective for ASUC with a reassuring safety profile. Upadacitinib use resulted in a significantly lower rate of colectomy by week 52, with higher rates of clinical remission, corticosteroid-free clinical remission, and biochemical remission during follow-up. Sequential salvage therapy may represent a viable therapeutic option for patients otherwise facing colectomy.

Schlagwörter

Stichwörter der Autor:innen

Acute Severe Ulcerative ColitisJanus Kinase InhibitorRescue TherapySequential Salvage TherapyTofacitinibUpadacitinib

Autor:innen und Institutionen

  • Department of Gastroenterology, Mater Hospital, Brisbane, Australia; Mater Research Institute, University of Queensland, South Brisbane, Australia. Electronic address: rob.gilmore@mater.org.au.
  • Department of Gastroenterology, Mater Hospital, Brisbane, Australia; Mater Research Institute, University of Queensland, South Brisbane, Australia.
  • Department of Gastroenterology, Mater Hospital, Brisbane, Australia.
  • Department of Gastroenterology, Austin Health, Melbourne, Australia.
  • Department of Gastroenterology, Alfred Health, Melbourne, Australia.
  • Department of Gastroenterology, Northern Health, Melbourne, Australia.

Zitieren

APA

Gilmore, R., Fernandes, R., Goetz, N., Chin, S., Con, D., De Cruz, P., Demase, K., Sparrow, M. P., Lucas, S., Garg, M., Tuttle, Z., Clark, N., Tassone, D., Ding, N., Loebenstein, M., Nguyen, A., Moore, G. T., Thin, L., MacFarlane, K., …, & An, Y. K. (2026). Janus Kinase Inhibitors for Acute Severe Ulcerative Colitis: Comparing Upadacitinib to Tofacitinib and Rescue to Sequential Salvage Therapy. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.09.017

Vancouver

Gilmore R, Fernandes R, Goetz N, Chin S, Con D, De Cruz P, et al. Janus Kinase Inhibitors for Acute Severe Ulcerative Colitis: Comparing Upadacitinib to Tofacitinib and Rescue to Sequential Salvage Therapy. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.09.017

BibTeX
@article{Gilmore2026,
  author = {Gilmore, Robert and Fernandes, Richard and Goetz, Naeman and Chin, Simone and Con, Daniel and De Cruz, Peter and Demase, Kathryn and Sparrow, Miles P and Lucas, Sarah and Garg, Mayur and Tuttle, Zachary and Clark, Nicholas and Tassone, Daniel and Ding, Nik and Loebenstein, Moshe and Nguyen, Andrew and Moore, Gregory T and Thin, Lena and MacFarlane, Kirsty and Lynch, Kate D and Subhaharan, Deloshaan and Mohsen, Waled and Haig, Adam and Day, Melissa and White, Lauren and Baker, Justin and Venugopal, Kannan and Tandon, Bhuwan and Bryant, Robert V and Etchegaray, Amirah and Tambakis, George and Walker, Gareth and Pelecanos, Anita and Begun, Jakob and An, Yoon-Kyo},
  title = {Janus Kinase Inhibitors for Acute Severe Ulcerative Colitis: Comparing Upadacitinib to Tofacitinib and Rescue to Sequential Salvage Therapy},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1016/j.cgh.2026.09.017}
}
Kostenlos starten →